ArticleThe Lancet. Oncology2020

Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials.

Alexander Drilon et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.